AMSBIO has announced the opening of a new North American headquarters with executive management facilities in Cambridge, Mass., for its U.S. subsidiary, AMSBIO LLC.
Commenting on this strategic move, Alex Sim, president, AMSBIO, said “The U.S. is the single largest market for our stem cell and regenerative medicine, glycobiology enzymes/substrates and tissue derived products. Drawing upon upon our in-depth expertise in extracellular matrices we are able to also provide elegant solutions for studying cell motility, migration, invasion and proliferation.” He added, “Our North American customer base has been growing strongly over recent years. From the new East Coast facility we will provide local informed service and support as well as next day delivery of a comprehensive range of enabling technology products to help improve the productivity of our U.S. customers.”
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology products and services for research and development in the medical, nutrition, cosmetics and energy industries. Widely acknowledged as experts in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance physiologically relevant screening outcomes and subsequently reduce drug development attrition rates. AMSBIO serves the European market from facilities in Switzerland, Germany, and the UK. This latter location provides the logistics and distribution services as well as housing a multi lingual marketing and technical staff made up of scientists with many years of experience in cutting edge technology.
Date: April 22, 2014
Filed Under: Drug Discovery